NDA 217370 · Alcon Labs INC
Tryptyr
Acoltremon · Ophthalmic · TRPM8 Thermoreceptor Agonist
NovelCDER novel approval, May 28, 2025: To treat the signs and symptoms of dry eye disease
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
May 28, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
3 Phase 3, 6 recruiting
FAERS reports
6,335
166 serious, 22 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 18, 2025.
TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease. TRYPTYR is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )
Mechanism: Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in dry eye disease is unknown.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TRYPTYR · ACOLTREMON 0.003% · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acoltremon" as an intervention, any sponsor and status, largest first.
- Switching From Restasis to TRYPTYRNot yet recruiting
Southern College of OptometryAcademic, hospital or other
NCT07267299 · 100 participants (planned) · Start Dec 1, 2025 · Primary completion Apr 1, 2026
Drug: acoltremon 0.003% · For: Dry Eye; Eye Diseases; Chronic Dry Eye
- Switching From Xiidra to TRYPTYRNot yet recruiting
Southern College of OptometryAcademic, hospital or other
NCT07267481 · 100 participants (planned) · Start Dec 15, 2025 · Primary completion Apr 15, 2026
Drug: acoltremon 0.003% · For: Dry Eye; Dry Eyes Chronic; Dry Eye Syndromes and 1 more
- A Study Designed to Evaluate Tear ProductionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06544707 · 81 participants · Start Oct 15, 2024 · Primary completion Jan 30, 2025
Drug: 0.003% AR-15512 ophthalmic solution · For: Dry Eye Disease
Sites: Newport Beach, California
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseasePivotal-lookingCompleted
Alcon ResearchIndustry
NCT06544694 · 80 participants · Start Oct 8, 2024 · Primary completion Mar 21, 2025
Drug: 0.003% AR-15512 ophthalmic solution · For: Dry Eye Disease
Sites: Louisville, Kentucky; Garner, North Carolina; Leland, North Carolina · 4 sites in all
Center for Sight Las VegasAcademic, hospital or other
NCT07281950 · 60 participants (planned) · Start Dec 15, 2025 · Primary completion Nov 30, 2026
Drug: acoltremon 0.003% · For: Dry Eye Disease (DED)
Sites: Las Vegas, Nevada
- A Study to Evaluate 0.003% AR-15512 Safety and Drop AttributesPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06660290 · 55 participants · Start Jan 15, 2025 · Primary completion Feb 6, 2025
Drug: 0.003% AR-15512 ophthalmic solution; Artificial tears · For: Dry Eye Disease
Sites: Newport Beach, California; Colorado Springs, Colorado; Andover, Massachusetts · 6 sites in all
NYU Langone HealthAcademic, hospital or other
NCT07732010 · 50 participants (planned) · Start Jul 6, 2026 · Primary completion Apr 20, 2027
Drug: TRYPTYR (Acoltremon ophthalmic solution 0.003%) · For: Dry Eye Disease (DED)
Sites: New York, New York
University of South FloridaAcademic, hospital or other
NCT07502378 · 50 participants (planned) · Start Apr 6, 2026 · Primary completion Mar 31, 2027
Drug: Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period. · For: Ocular Surface Disease; Neurotrophic Keratopathy Stage 1
Sites: Tampa, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation3,268
- drug ineffective1,382
- eye pain1,110
- dry eye604
- vision blurred511
- ocular hyperaemia489
- lacrimation increased280
- ocular discomfort260
- eye pruritus203
- condition aggravated190
- headache186
- visual impairment143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 1,312 |
| 2026 | 5,022 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies.
Pattar GR, Wirta D, Jerkins G, et al. · Ophthalmology 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.